Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma
- PMID: 30080736
- DOI: 10.1097/SLA.0000000000002889
Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma
Erratum in
-
Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma: Erratum.Ann Surg. 2019 Apr;269(4):e59. doi: 10.1097/SLA.0000000000003141. Ann Surg. 2019. PMID: 30702456 No abstract available.
Abstract
Objective: The aim of this study was to estimate probabilities of achieving the statistical cure from hepatocellular carcinoma (HCC) with hepatic resection (HR) and liver transplantation (LT).
Background: Statistical cure occurs when the mortality of a specific population returns to values of that of general population. Resection and transplantation are considered potentially curative therapies for HCC, but their effect on the residual entire life-expectancy has never been investigated.
Methods: Data from 3286 HCC patients treated with LT (n = 1218) or HR (n = 2068) were used to estimate statistical cure. Disease-free survival (DFS) was the primary survival measure to estimate cure fractions through a nonmixture model. Overall survival (OS) was a secondary measure. In both, patients were matched with general population by age, sex, year, and race/ethnicity. Cure variations after LT were also adjusted for different waiting-list drop-outs.
Results: Considering DFS, the cure fraction after LT was 74.1% and after HR was 24.1% (effect size >0.8). LT outperformed HR within all transplant criteria considered (effect size >0.8), especially for multiple tumors (>0.9) and even in presence of a drop-out up to 20% (>0.5). Considering OS, the cure fraction after LT marginally increased to 75.8%, and after that HR increased to 40.5%. The effect size of LT over HR in terms of cure decreased for oligonodular tumors (<0.5), became small for drop-out up to ∼20% (<0.2), and negligible for single tumors <5 cm (∼0.1).
Conclusion: As other malignancies, statistical cure can occur for HCC, primarily with LT and secondarily with HR, depending on waiting-list capabilities and efficacy of tumor recurrence therapies after resection.
Comment in
-
Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference.Transl Gastroenterol Hepatol. 2018 Dec 14;3:104. doi: 10.21037/tgh.2018.12.03. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 30701211 Free PMC article. No abstract available.
-
Hepatectomy bridges to transplant-the road to cure?Hepatobiliary Surg Nutr. 2019 Feb;8(1):72-73. doi: 10.21037/hbsn.2018.11.08. Hepatobiliary Surg Nutr. 2019. PMID: 30881972 Free PMC article. No abstract available.
-
Surgery for hepatocellular carcinoma can provide the same life-expectancy as transplant of that of general population.Hepatobiliary Surg Nutr. 2019 Apr;8(2):151-152. doi: 10.21037/hbsn.2018.11.17. Hepatobiliary Surg Nutr. 2019. PMID: 31098365 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials